Interesting info...Larry to present in May 2016
1:30 pm INTREPID-2566 : A Phase II Clinical Trial of NNZ-2566 (trofinetide) in Moderate to Severe TBI
Overview of the methodology, endpoints and analytical methodology for the INTREPID-2566 trial and preliminary findings, if available. The presentation will emphasize the role of biomarkers in the analysis of the study.
Larry Glass, Chief Science Officer, Neuren Pharmaceutical
At the 6th Annual Traumatic Brain Injury Conference in Washington DC.
http://tbiconference.com/home/index.php/newagenda
- Forums
- ASX - By Stock
- NEU
- Larry Glass to present study in May
Larry Glass to present study in May
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NVA
Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter
IGO
IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.91 |
Change
-0.260(1.29%) |
Mkt cap ! $2.576B |
Open | High | Low | Value | Volume |
$20.45 | $20.45 | $19.87 | $1.085M | 54.12K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 226 | $19.89 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.91 | 42 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 242 | 19.890 |
7 | 1328 | 19.880 |
4 | 174 | 19.870 |
5 | 629 | 19.860 |
5 | 1246 | 19.850 |
Price($) | Vol. | No. |
---|---|---|
19.910 | 56 | 4 |
19.920 | 427 | 5 |
19.930 | 193 | 2 |
19.940 | 195 | 2 |
19.950 | 543 | 5 |
Last trade - 12.50pm 29/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |